LEXINGTON, Mass., Sept. 14, 2021 /PRNewswire/ -- iSpecimen
Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an
online marketplace for human biospecimens, today announced that it
will be included in the Russell Microcap® Index,
effective after the U.S. market opens on September 20, 2021, as part of the 2021 Russell
Membership in the Russell Microcap® Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. Russell indexes are
part of FTSE Russell, a leading global index provider. FTSE Russell
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes.
"Our inclusion to the Russell Microcap Index is an important
milestone and reflects iSpecimen's efforts and growth as we
continue to streamline the biospecimen procurement process. We
believe joining this index will bolster our visibility and exposure
across the global investment community," said Christopher Ianelli, MD, PhD, CEO and President
of iSpecimen. "This also comes at an important time for us, as we
continue to refine the iSpecimen Marketplace platform to empower
researchers in advancing scientific discovery."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $10.6 trillion in assets were benchmarked against
Russell's U.S. indexes, as of the end of 2020. For more information
on the Russell Microcap® Index and the Russell indexes
reconstitution, go to the "Russell Reconstitution" section on the
FTSE Russell website.
About FTSE Russell
FTSE Russell is a global index
leader that provides innovative benchmarking, analytics and data
solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset
classes in more than 70 countries, covering 98% of the investable
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$17.9 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks
have chosen FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
FTSE Russell is wholly owned by London Stock Exchange Group. For
more information, visit www.ftserussell.com.
iSpecimen offers an online marketplace
for human biospecimens, connecting life scientists in commercial
and non-profit organizations with healthcare providers that have
access to patients and specimens needed for medical discovery.
Proprietary, cloud-based technology enables scientists to
intuitively search for specimens and patients across a federated
partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about
iSpecimen, please visit www.ispecimen.com.
This press release may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risks factors contained
in the Company's filings with the Securities and Exchange
Commission, which are available for review at www.sec.gov.
Forward-looking statements speak only as of the date they are made.
New risks and uncertainties arise over time, and it is not possible
for the Company to predict those events or how they may affect the
Company. If a change to the events and circumstances reflected in
the Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
For further information, please contact:
KCSA Strategic Communications
Allison Soss / Scott Eckstein
View original content to download
SOURCE iSpecimen Inc.